drugset / Trial / NCT07302919
Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma
RandomizedParallel-groupQuadruple-blindTreatment
Summary
IMPACT-TACE is an investigator-initiated, prospective, multicenter, randomized, double-blinded, interventional trial to test the hypothesis that the simultaneous application of doxorubicin with the ABCB1 inhibitor nicardipine would significantly improve the success rate of TACE treatment.
Timeline
- Start
- 2026-02-16
- Primary completion
- 2028-06
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nicardipine | Small molecule | 0.3 mg/ml | Other |
| Background | Doxorubicin | Other / unclassified | 33 mg/ml | Other |